Sarepta Therapeutics (SRPT) Long-Term Investments (2013 - 2026)

Sarepta Therapeutics' Long-Term Investments history runs 14 years deep, the most recent figure standing at $270.7 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 148.06% year-over-year to $270.7 million in Q1 2026; TTM through Mar 2026 was $270.7 million, a 148.06% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, down 99.21% from the prior year.
• Long-Term Investments rose to $270.7 million in Q1 2026 per SRPT's latest filing, from $1.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $324.1 million in Q2 2025 and bottomed at $1.0 million in Q4 2025.
• The 5-year median for Long-Term Investments is $31.0 million (2023), against an average of $62.6 million.
• Biggest YoY gain for Long-Term Investments was 4161.11% in 2025; the steepest drop was 99.21% in 2025.
• Year by year, Long-Term Investments stood at $31.3 million in 2022, then slumped by 79.16% to $6.5 million in 2023, then soared by 1940.19% to $133.2 million in 2024, then tumbled by 99.21% to $1.0 million in 2025, then jumped by 25730.15% to $270.7 million in 2026.
• Per Business Quant, the three latest SRPT Long-Term Investments figures stand at $270.7 million (Q1 2026), $1.0 million (Q4 2025), and $8.2 million (Q3 2025).